Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 294
- Registration Number
- NCT05489848
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 582
- Registration Number
- NCT05489211
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Role of the ATP7A Transporter in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 40
- Registration Number
- NCT05490407
- Locations
- 🇸🇮
Department of Gynecology, Division of Gynecology and Obstetrics, Ljubljana University Medical Center, Ljubljana, Slovenia
🇸🇮Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana., Ljubljana, Slovenia
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 632
- Registration Number
- NCT05487391
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai. China, Shanghai, China
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Okayama University
- Target Recruit Count
- 23
- Registration Number
- NCT05485766
- Locations
- 🇯🇵
St. Luke's International Hospital, Tokyo, Japan
🇯🇵Aichi Cancer Center, Nagoya, Japan
🇯🇵Okayama University Hospital, Okayama, Japan
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Jin Hyoung Kang
- Target Recruit Count
- 28
- Registration Number
- NCT05477615
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, Republic of
🇰🇷Gachon University Gil Medical Center, Seoul, Korea, Republic of
🇰🇷Korea University Guro Hosptial, Seoul, Korea, Republic of
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Pamela Munster
- Registration Number
- NCT05472220
A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 64
- Registration Number
- NCT05469178
- Locations
- 🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland, United States
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT05459129
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇦🇺Sir Charles Gairdner Hospital; Medical Oncology, Perth, Western Australia, Australia
🇫🇷Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France
A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Lantern Pharma Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05456256
- Locations
- 🇺🇸
Los Angeles Cancer Network, Fountain Valley, California, United States
🇯🇵Hokkaido Cancer Center, Sapporo-Shi, Hokkaido, Japan
🇯🇵Kanagawa Cancer Center Hospital, Yokohama-Shi, Kanagawa, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.